Lilly’s Alimta breaks 70 limit, keeping NSCLC at bay in elderly sub-group
This article was originally published in Scrip
An analysis of the performance in the elderly of Lilly's Alimta (pemetrexed for injection) in the most common form of lung cancer, nonsquamous non-small cell lung cancer, has shown that the drug reduced the risk of disease progression by 65%. The drug was given as maintenance therapy following first line treatment with Alimta plus cisplatin induction therapy and provided patients over 70 years of age median progression-free survival of 6.4 months, compared with 3.0 months for those in the control group. Its impact on younger patients was much less marked.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.